linjc16/ctgov huggingface dataset:
Evaluation of Information Displays-A Paper, Computer and Simulator Based Study

Study Overview
=================
Brief Summary
-----------------
Our objective is to develop intuitive, meaningful and ergonomically efficient informative displays specific to the user's domain.

Detailed Description
-----------------
Typically information monitors present numeric values, waveforms, alarms and informative sounds in a single sensor single indicator manner (5). In an effort to improve the situational awareness of the end user (6), we design and develop various visual metaphors and audible representations of information to communicate the past, present, and future status of a complex system. Our studies will identify the visual and auditory elements that optimize the presentation of critical domain specific information in an intuitive, meaningful manner as well as communicate critical events efficiently and saliently as they arise.

Official Title
-----------------
Evaluation of Information Displays-A Paper, Computer and Simulator Based Study

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: projected end users of the domain specific visualizations. experts and novice users of the domain specific information. Exclusion Criteria: Subjects having been exposed to a particular visualization prior to testing.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1 Visualization users<br>End users of the domain specific visualizations. | Other: observational<br>* presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjects will be able to identify components of the visualization from predetermined lists of answers. |  | At time of observation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Display development, Intuitive display use, visualizations are intuitive
Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala

Study Overview
=================
Brief Summary
-----------------
Hippocampus and amygdala are parts of the brain involved in the recognition of emotions, memories, memory, language ... It is therefore very important to protect them during irradiation of the brain. The aim of this study is to evaluate cerebral irradiation with saving hippocampus and amygdala protects these brain functions in patients with small cell lung cancer (SCLC) Radiotherapy of the brain

Official Title
-----------------
Savings of Hippocampus and Amygdala by Archetherapy in Cerebral Prophylactic Irradiation in Patients With Limited and / or Extended, Responsive or Stable Small Cell Lung Cancer (SCLC)

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Radiation: Irradiation prophyllactique cérébrale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years of age Patients with a limited SCLC demonstrated histologically responsive or stable to radiochemotherapy or patients with a histologically proven extended SCLC responding to chemotherapy. WHO Performance Index 0-1 and / or Karnovsky Index> 70 Possibility of long-term monitoring Exclusion Criteria: Concomitant chemotherapy Impossibility of performing an MRI or CT without injection Presence of cerebral metastases History of cerebral irradiation at any time Patient suffering from severe collagenosis Patient with cognitive disorders with MMSE score <24

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Irradiation prophyllactique cérébrale<br> | Radiation: Irradiation prophyllactique cérébrale<br>* Irradiation prophyllactique cérébrale<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive function | Evaluate the cognitive function with Wechsler Memory Scale IV (WMS-IV) test | until 18 months after inclusion of patient | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary effects according the CTCAE v.4 criteria | Evaluate the toxicity according the CTCAE v.4 criteria | until 18 months after inclusion of patient | 
| Appearance of brain metastases and their location | Evaluate the brain control with brain MRI | until 18 months after inclusion of patient | 
| Quality of life (QOL) of patients | Evaluate QOL with FACT-BR test (Functional Assessment of Cancer Therapy-Brain) | until 18 months after inclusion of patient |
Intrauterine Saline Washing for Detection Endometrial Disease in Patients With Abnormal Uterine Bleeding

Study Overview
=================
Brief Summary
-----------------
Investigator will examined the diagnostic effect of the endometrial washing by saline. Because this technique more less painful and easier compared to endometrial curettage. Participants will separate into two groups. In study groups before endometrial curettage 5 cc saline infused to the endometrial cavity then aspirate and put into thin prep to examined. After this procedure routine endometrial curettage will be done. In control group only endometrial curettage will be done. Pathologic results of thin prep and curettage will compared.

Conditions
-----------------
Endometrial Disease

Intervention / Treatment
-----------------
* Procedure: Endometrial saline plus curettage
* Procedure: Endometrial curettage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Abnormal uterine bleeding Exclusion Criteria: Involuntary, under 35 years old,

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Endometrial saline plus curettage<br>5 cc saline infused to the endometrial cavity and aspirated. Then routine endometrial curettage performed for same participant. | Procedure: Endometrial saline plus curettage<br> <br> |
| Active Comparator: Endometrial curettage<br>Only routine endometrial curettage performed | Procedure: Endometrial curettage<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cervical cytological results according to Bethesda 2003 | for endometrial washing sample | 1 month | 
| Endometrial hyperplasiz classification according to World Health Organization 2013 | for endometrial curretage sampling | 1 month |
Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

Study Overview
=================
Brief Summary
-----------------
Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of < 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration

Official Title
-----------------
Evaluation of the Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

Conditions
-----------------
Pediatric Solid Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Patients of pediatric age up to 22 years included at the time of molecular analysis Histological carcinological diagnosis performed at HUS Carcinological follow-up performed at HUS Patients with a solid tumor of unfavorable prognosis, refractory or in relapse Molecular analysis performed on tumor or blood samples Adult patients who do not object to the re-use of their personal data for medical research purposes Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes. Criteria for non-inclusion Molecular biology results not usable due to poor sample quality or insufficient genetic material Patients who have expressed their opposition to participate in the study Parental authority holders who have expressed their opposition to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective description of the clinical and therapeutic impact of the systematic performance of molecular analyzes on solid tumors | The aim of this retrospective study is to improve and harmonize international practices | up to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pediatric solid tumors, BROAD GENOMIC STUDIES, SOLID CANCERS, Genomic medicine
HPV as a Possible Cause of Azoospermia

Study Overview
=================
Brief Summary
-----------------
Azoospermia is found in 5-20% of all men suffering from infertility, and in more than 20% azoospermia remains unexplained. The investigators suggest, that HPV may be an etiological factor in azoospermia and reduced sperm production. The investigators plan to examine the occurrence of HPV in testicular tissue from 100 azoospermic men and to compare with the HPV occurrence in testicular tissue from a control group of 40 normal, healthy men undergoing vasectomy. Since HPV, in a recent Danish study, was detected on sperm in 16% of 188 randomly selected semen donors, the investigators also plan to examine the occurrence of HPV on sperm ejaculated during the last week before vasectomy. If HPV should be found in testicular tissue from men belonging to the control group, it will be highly relevant to compare with the HPV occurrence on sperm ejaculated from the men in concern. A Linear Array HPV Genotyping Kit from Roche will be used for detection of HPV in testicular tissue and ejaculates. In total, with this test kit 37 HPV genotypes are examined for, including 13 high risk types.

Conditions
-----------------
HPV in Testis Tissue

Intervention / Treatment
-----------------
* Procedure: Testicular biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men with azoospermia (Group 1) and proven fertile men undergoing vasectomy (Group 2) Exclusion Criteria: Men with testicular abnormalities (Group 2) Men who do not understand the purpose and possible consequences of the study (both groups)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Azoospermic men<br> | Procedure: Testicular biopsy<br> <br> |
| Men with proven fertility<br> | Procedure: Testicular biopsy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HPV DNA in testicular tissue | In tissue from both azoospermic and proven fertile men | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HPV DNA in ejaculates | In ejaculates from the proven fertile men | Two years |
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.

Official Title
-----------------
Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon®

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Drug: Interferon beta-1b (Betaseron, BAY86-5046)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Relapsing Remitting Multiple Sclerosis (RRMS), and treated with Betaferon, with the decision for treatment made at the discretion of the attending physician, documented with a prescription of Betaferon by the physician EDSS 0 - 6 Written informed consent Exclusion Criteria: Patients who do not meet the local indication criteria for Betaferon treatment. Contraindications listed in the local SmPCs have to be considered. Patients with a history of severe head trauma. Patients with alcohol and/or drug abuse. Patients with mental retardation. Patients with learning disability.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Interferon beta-1b (Betaseron, BAY86-5046)<br>* Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive performance as measured by SDMT (Symbol Digit Modalities Test) |  | 24 months | 
| Physical activity as measured by the Baecke questionnaire |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disability as measured by EDSS (Expanded Disability Status Scale) |  | 24 months | 
| Fatigue as measured by FSMC (Fatigue Scale for Motor and Cognitive Functions) |  | 24 months | 
| Depression as measured by the CES-D (Center for Epidemiologic Studies Depression) |  | 24 months | 
| Quality of life as measured by the SF-12 (Mental and physical health-scale measure of quality of life) |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cognition, Physical Activity, Relapsing Remitting Multiple Sclerosis
Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study

Study Overview
=================
Brief Summary
-----------------
The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients. This model will inform the selection of the outcomes and potential mediators and moderators of these outcomes, to inform the debate over utility, risks, and benefits of clinical incorporation of multiplex testing for breast cancer susceptibility.

Official Title
-----------------
Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study

Conditions
-----------------
BRCA1/2 Negative

Intervention / Treatment
-----------------
* Other: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Women and men (at least 18 YO) 2. English speaking AND 3. Negative for BRCA1 and BRCA2 mutations Exclusion Criteria: 1. Non English speaking patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaires|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Completion of questionnaires |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patients
Levels of Circulating T Cells Expressing VLA-1 Collagen Receptors

Study Overview
=================
Brief Summary
-----------------
The examination of the percentage of peripheral T cells carrying VLA-1 in ischemic heart disease patients. The hypothesis is that the percentage levels of cells carrying this integrin rise according to the severity of the ischemic heart disease.

Detailed Description
-----------------
Atherosclerosis is considered an inflammatory disease in which lymphocytes have an important role. The study was disigned to find out the changes in T cell levels carrying VLA-1 involvement in this process.

Official Title
-----------------
VLA-1 Receptors on Peripheral T Cells in Ischemic Heart Disease Patients

Conditions
-----------------
Ischemic Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of acute MI for group 1 clinical diagnosis of ACSl for group 2 clinical diagnosis of Chronic Heart Disease for groups 3 and 4 Chest pain but normal heart scan for group 5 Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |
| 2<br> | |
| 3<br> | |
| 4<br> | |
| 5<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The differance in percentage of T cells in the 5 different groups involved. |  | 2002-2006 |
Using Urine Color as a Marker of Hydration Status

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to determine if rapid changes in hydration status could be determined by urine color expressed in CIE color space

Detailed Description
-----------------
The study will examine if urine color expressed in CIE color space can reflect hydration status. Hydration staus will be rapidly altered via exercise in the heat.

Official Title
-----------------
Urine Color Expressed in CIE L*a*b* Colorspace During Rapid Changes in Hydration Status

Conditions
-----------------
Dehydration

Intervention / Treatment
-----------------
* Other: dehydration and rehydration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-35 years of age, no previous heat intolerance Exclusion Criteria: - Pregnant women,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: urine color was measured during dehydration and rehydration
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dehydration to rehydration<br>subjects were rehydrated following 2% dehydration | Other: dehydration and rehydration<br>* dehydration and rehydration<br>|
| Experimental: euhydration to dehydration<br>subjects were dehydrated by 2% with exercise in the heat | Other: dehydration and rehydration<br>* dehydration and rehydration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| can urine color expressed in CIE color space reflect hydration status | urine color expressed in CIE color space | one hour dehydration and rehydration |